MedTrace Logo

To Evaluate the Bioavailability of a Tablet of AZD1656

NCT00817505 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2009-11-03

No results posted yet for this study

Summary

To evaluate the bioavailability of a tablet of AZD1656.

Conditions

Interventions

DRUG

AZD1656

Single dose oral tablet

DRUG

AZD1656

Single dose oral suspension

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof · AstraZeneca R&D Mölndal

  • Emanuel P DeNoia, MD · Healthcare Discoveries LLC Icon Development Solutions

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-03-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817505 on ClinicalTrials.gov